PE20120666A1 - Inhibidores de los virus flaviviridae - Google Patents

Inhibidores de los virus flaviviridae

Info

Publication number
PE20120666A1
PE20120666A1 PE2012000069A PE2012000069A PE20120666A1 PE 20120666 A1 PE20120666 A1 PE 20120666A1 PE 2012000069 A PE2012000069 A PE 2012000069A PE 2012000069 A PE2012000069 A PE 2012000069A PE 20120666 A1 PE20120666 A1 PE 20120666A1
Authority
PE
Peru
Prior art keywords
trans
carboxyl
methyl
thiophene
cyclohexanocarbonyl
Prior art date
Application number
PE2012000069A
Other languages
English (en)
Inventor
Eda Canales
Lee Chong
Michael O'neil Hanrahan Clarke
Edward Doerffler
Scott E Lazerwith
Willard Lew
Michael Mertzman
Philip A Morganelli
William J Watkins
Hong Ye
Qi Liu
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of PE20120666A1 publication Critical patent/PE20120666A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE TIOFENO-2-CARBOXILICO DE FORMULA (I) DONDE R1 ES ALQUILO(C1-C12), ALQUENILO(C2-C12), CICLOALQUILO(C3-C12), ENTRE OTROS; R2 ES ALQUINILO(C2-C12), CICLOALQUILO(C3-C12), ARILO(C6-C14), ENTRE OTROS; R3 ES ALQUILENO(C1-C12), ALQUENILENO(C2-C12), ARILENO(C6-C14), ENTRE OTROS; L ES -O-, -S-, -S(O)- O -S(O)2-; HET ES HETEROCICLILO DE 3 A 12 MIEMBROS O HETEROARILO DE 3 A 14 MIEMBROS OPCIONALMENTE SUSTITUIDOS CON Q4, EN DONDE Q4 ES HALOGENO, OXO, NO2, N(=O), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ACIDO 5-(3,3-DIMETIL-BUT-1-INIL)-3-{(TRANS-4-METIL-CICLOHEXANOCARBONIL)-[TRANS-4-(PIRAZIN-2-ILOXI)-CICLOHEXIL]-AMINO}-TIOFENO-2-CARBOXILICO; ACIDO 5-(3,3-DIMETIL-BUT-1-INIL)-3-{(TRANS-4-METIL-CICLOHEXANOCARBONIL)-[TRANS-4-(6-METIL-PIRIDAZIN-3-ILOXI)-CICLOHEXIL]-AMINO}-TIOFENO-2-CARBOXILICO; ACIDO 5-(3,3-DIMETIL-BUT-1-INIL)-3-{(TRANS-4-METIL-CICLOHEXANOCARBONIL)-[TRANS-4-(PIRIDIN-3-ILOXI)-CICLOHEXIL]-AMINO}-TIOFENO-2-CARBOXILICO; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LOS VIRUS FLAVIVIRIDAE SIENDO UTILES EN EL TRATAMIENTO DE LA INFECCION POR EL VIRUS DE LA HEPATITIS C (HCV)
PE2012000069A 2009-07-21 2010-07-19 Inhibidores de los virus flaviviridae PE20120666A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22736709P 2009-07-21 2009-07-21
US24091109P 2009-09-09 2009-09-09
US35946610P 2010-06-29 2010-06-29

Publications (1)

Publication Number Publication Date
PE20120666A1 true PE20120666A1 (es) 2012-06-01

Family

ID=42711860

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000069A PE20120666A1 (es) 2009-07-21 2010-07-19 Inhibidores de los virus flaviviridae

Country Status (26)

Country Link
US (2) US8569302B2 (es)
EP (1) EP2475657B1 (es)
JP (2) JP5841531B2 (es)
KR (1) KR20120051022A (es)
CN (1) CN102471327A (es)
AP (1) AP3409A (es)
AR (1) AR077765A1 (es)
AU (1) AU2010276441B2 (es)
CA (1) CA2767088C (es)
CL (1) CL2012000147A1 (es)
CO (1) CO6491049A2 (es)
CR (1) CR20120081A (es)
DK (1) DK2475657T3 (es)
EA (1) EA020816B1 (es)
EC (1) ECSP12011684A (es)
ES (1) ES2427342T3 (es)
HK (1) HK1166788A1 (es)
IL (1) IL217243A (es)
MX (1) MX2012000959A (es)
NZ (1) NZ597528A (es)
PE (1) PE20120666A1 (es)
SG (1) SG177709A1 (es)
TW (1) TW201116525A (es)
UY (1) UY32793A (es)
WO (1) WO2011011303A1 (es)
ZA (1) ZA201200940B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102471327A (zh) * 2009-07-21 2012-05-23 吉里德科学公司 黄病毒科病毒的抑制剂
WO2011031669A1 (en) 2009-09-09 2011-03-17 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
PT2480559E (pt) 2009-09-21 2013-10-02 Gilead Sciences Inc Processos e intermediários para a preparação de análogos de 1'-ciano-carbanucleósido
AP2012006413A0 (en) 2010-01-15 2012-08-31 Gilead Sciences Inc Inhibitors of flaviviridae viruses
PT2523950T (pt) * 2010-01-15 2017-06-01 Gilead Sciences Inc Inibidores dos vírus flaviridae
CA2803248A1 (en) * 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
WO2012010663A1 (en) 2010-07-22 2012-01-26 Novartis Ag 2,3,5-trisubstituted thiophene compounds and uses thereof
UA111163C2 (uk) 2010-07-22 2016-04-11 Гайлід Сайєнсіз, Інк. Способи й сполуки для лікування вірусних інфекцій paramyxoviridae
PT2734515E (pt) * 2011-07-13 2016-03-11 Gilead Sciences Inc Derivados de ácido tiofen-2-carboxílico úteis como inibidores de vírus flaviviridae
CA2877786C (en) 2012-06-26 2020-08-25 Bayer Pharma Aktiengesellschaft N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products
US8841340B2 (en) 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
US8927741B2 (en) 2012-08-17 2015-01-06 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8759544B2 (en) * 2012-08-17 2014-06-24 Gilead Sciences, Inc. Synthesis of an antiviral compound
CN102964295B (zh) * 2012-12-17 2014-08-20 寿光富康制药有限公司 一种2-取代-4-（哌啶基甲基）吡啶的制备方法
EP2762124A1 (en) * 2013-01-31 2014-08-06 IP Gesellschaft für Management mbH Packaging comprising administration units of polymorphs, amorphous forms or solvates
US9492438B2 (en) * 2014-07-25 2016-11-15 Bette Pollard Amphiphilic pyridinum compounds to treat epilepsy and other disorders of the nervous system
TWI740546B (zh) 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
KR20230130175A (ko) 2014-12-26 2023-09-11 에모리 유니버시티 Ｎ4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도
EP3785717B1 (en) 2015-09-16 2022-01-05 Gilead Sciences, Inc. Methods for treating coronaviridae infections
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
PL3464336T3 (pl) 2016-06-01 2022-05-16 Athira Pharma, Inc. Związki
ES2961460T3 (es) 2017-03-14 2024-03-12 Gilead Sciences Inc Métodos para tratar las infecciones por coronavirus felinas
WO2018204198A1 (en) 2017-05-01 2018-11-08 Gilead Sciences, Inc. Crystalline forms of (s) 2 ethylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
US10675296B2 (en) 2017-07-11 2020-06-09 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
AU2018378832B9 (en) 2017-12-07 2021-05-27 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US11660307B2 (en) 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
WO2021183750A2 (en) 2020-03-12 2021-09-16 Gilead Sciences, Inc. Methods of preparing 1'-cyano nucleosides
WO2021207049A1 (en) 2020-04-06 2021-10-14 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
EP4157272A1 (en) 2020-05-29 2023-04-05 Gilead Sciences, Inc. Remdesivir treatment methods
MX2022016405A (es) 2020-06-24 2023-01-30 Gilead Sciences Inc Análogos de nucleósido de 1¿-ciano y usos de estos.
JP2023540225A (ja) 2020-08-27 2023-09-22 ギリアード サイエンシーズ， インコーポレイテッド ウイルス感染症の治療のための化合物及び方法
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
TW202400185A (zh) 2022-03-02 2024-01-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861421A (en) * 1995-12-21 1999-01-19 Smithkline Beecham Corporation 4,4-(disubstituted) cyclohexan-1-one monomers and related compounds
US20020002199A1 (en) * 1998-03-12 2002-01-03 Lone Jeppesen Modulators of protein tyrosine phosphatases (ptpases)
US20050119332A1 (en) * 1998-03-12 2005-06-02 Lone Jeppesen Substituted thiophene compounds as modulators of protein tyrosine phosphatases (PTPases)
KR100900304B1 (ko) * 2001-06-11 2009-06-02 바이로켐 파마 인코포레이티드 플라비 바이러스 감염용 항바이러스제로서의 티오펜 유도체
CA2449999C (en) 2001-06-11 2012-07-31 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
ES2345438T3 (es) * 2002-12-10 2010-09-23 Virochem Pharma Inc. Compuestos y metodos para el tratamiento o prevencion de infecciones por flavivirus.
NZ540799A (en) 2002-12-10 2008-09-26 Virochem Pharma Inc Compounds and methods for the treatment or prevention of flavivirus infections
DE10359791A1 (de) * 2003-12-19 2005-07-21 Bayer Healthcare Ag Substituierte Thiophene
WO2005081954A2 (en) * 2004-02-25 2005-09-09 Wyeth Inhibitors of protein tyrosine phosphatase 1b
AU2005228899A1 (en) * 2004-03-30 2005-10-13 Novartis Vaccines And Diagnostics, Inc. Substituted thiophene derivatives as anti-cancer agents
DE102005028077A1 (de) 2004-12-22 2006-07-13 Aicuris Gmbh & Co. Kg Alkinyl-substituierte Thiophene
DE102004061746A1 (de) * 2004-12-22 2006-07-06 Bayer Healthcare Ag Alkinyl-substituierte Thiophene
CN101218224B (zh) * 2005-05-13 2013-05-08 Viro化学制药公司 治疗或预防黄病毒感染的组合物和方法
AU2007214710A1 (en) * 2006-02-15 2007-08-23 Sanofi-Aventis Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
JP5290186B2 (ja) * 2006-11-15 2013-09-18 ヴァイロケム ファーマ インコーポレイテッド フラビウイルス感染症の治療または予防用のチオフェン類似体
ATE524465T1 (de) * 2006-11-17 2011-09-15 Glaxosmithkline Llc 2-carboxy-thiophen-derivate als viruzide
CA2745119A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
CN102471327A (zh) * 2009-07-21 2012-05-23 吉里德科学公司 黄病毒科病毒的抑制剂
WO2011031669A1 (en) 2009-09-09 2011-03-17 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
EP2504329A1 (en) 2009-11-25 2012-10-03 Vertex Pharmaceuticals Incorporated 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections
AP2012006413A0 (en) * 2010-01-15 2012-08-31 Gilead Sciences Inc Inhibitors of flaviviridae viruses
PT2523950T (pt) * 2010-01-15 2017-06-01 Gilead Sciences Inc Inibidores dos vírus flaviridae
CA2803248A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections

Also Published As

Publication number Publication date
TW201116525A (en) 2011-05-16
DK2475657T3 (da) 2013-09-23
KR20120051022A (ko) 2012-05-21
AU2010276441B2 (en) 2015-07-02
JP2015205940A (ja) 2015-11-19
US20140030223A1 (en) 2014-01-30
CA2767088C (en) 2018-07-10
MX2012000959A (es) 2012-03-06
ES2427342T3 (es) 2013-10-30
AU2010276441A1 (en) 2012-02-02
CN102471327A (zh) 2012-05-23
CO6491049A2 (es) 2012-07-31
ECSP12011684A (es) 2012-04-30
AR077765A1 (es) 2011-09-21
ZA201200940B (en) 2014-07-30
CR20120081A (es) 2012-07-04
IL217243A (en) 2014-07-31
NZ597528A (en) 2014-08-29
EP2475657B1 (en) 2013-06-12
HK1166788A1 (es) 2012-11-09
EA201290053A1 (ru) 2012-07-30
AP2012006085A0 (en) 2012-02-29
IL217243A0 (en) 2012-02-29
JP2012533630A (ja) 2012-12-27
JP5841531B2 (ja) 2016-01-13
WO2011011303A1 (en) 2011-01-27
CA2767088A1 (en) 2011-01-27
US8569302B2 (en) 2013-10-29
UY32793A (es) 2011-01-31
EP2475657A1 (en) 2012-07-18
US20110020278A1 (en) 2011-01-27
AP3409A (en) 2015-08-31
CL2012000147A1 (es) 2012-09-07
EA020816B1 (ru) 2015-01-30
SG177709A1 (en) 2012-02-28

Similar Documents

Publication Publication Date Title
PE20120666A1 (es) Inhibidores de los virus flaviviridae
PE20121479A1 (es) Inhibidores del virus de la hepatitis c
PE20140109A1 (es) Inhibidores del virus de la hepatitis c
PE20130281A1 (es) Derivados de acido 5-alquinil-3-amida-2-tiofeno-carboxilico como inhibidores del virus flaviviridae
PE20090630A1 (es) Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
PE20070124A1 (es) Derivados de heteroaril para tratar virus
CY1113752T1 (el) Μακροκυκλικες ενωσεις κινοξαλινης ως αναστολεις πρωτεασεις ns3 του hcv
NO341663B1 (no) Cyklopropyl-kondenserte indolobenzaepin HCV NS5B inhibitorer
PE20080992A1 (es) Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c
EA201000201A1 (ru) Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
NO20084645L (no) Cyklopropyl kondenserte indolobenzazepin HCV NS5B inhibitorer
AR078976A1 (es) Inhibidores heterociclicos de la proteina ns5a codificada por el virus de la hepatitis c(vhc), composiciones farmaceuticas que los comprenden y uso de los mismos para tratar infecciones por vhc
PE20071326A1 (es) Inhibidores de la polimerasa viral
AR075510A1 (es) Inhibidores del virus de la hepatitis c
PE20120257A1 (es) Analogos carba-nucleosidicos para tratamiento antiviral
EA201100482A1 (ru) Кристаллические формы 2-тиазолил-4-хинолинилоксипроизводного, активного ингибитора hcv
EA201491179A1 (ru) 2',4'-дифтор-2'-метил замещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с
EA201171152A1 (ru) Ингибиторы вируса гепатита c
EA201001273A1 (ru) Ингибиторы вируса гепатита с
CY1111423T1 (el) Αναστολεις ns5b hcv
PE20120995A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
PE20091841A1 (es) Inhibidores del virus de hepatitis c
PA8733401A1 (es) Compuestos de pirro[1,2-b]piridazinona
PE20070814A1 (es) Compuestos derivados de 2-carboxitiofeno como inhibidores de la polimerasa del virus de la hepatitis c (hcv)
DK2209789T3 (da) Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere

Legal Events

Date Code Title Description
FC Refusal